Stuart Charles Williamson (Stuart Williamson, Stuart C Williamson)

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 17

Top Venues

British journal of cancer

Science signaling

NPJ breast cancer

Cancer research

AstraZeneca UK Ltd

Newcastle University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

AstraZeneca UK Ltd Jan 06 2020

United Kingdom

Senior Scientist

CRUK Manchester Institute Sep 01 2014 - Nov 30 2019

United Kingdom

Post-doctoral researcher :: Clinical and Experimental Pharmacology Group

Stanford University Sep 01 2018 - Mar 21 2019

United States

Visiting Fulbright Scholar :: Sage Lab

Newcastle University

United Kingdom

Research Associate :: Northern Institute for Cancer Research

Education History

Newcastle University

United Kingdom

PHD :: Northern Institute for Cancer Research

Publications

Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Emily C Erickson, Inchul You, Grace E Perry, Aurélien J F Dugourd, Katherine Aleisha Donovan, Claire Crafter, Jeffrey W Johannes, Stuart Charles Williamson, Jennifer I Moss, Susana Ros, Robert E Ziegler, Simon T Barry, Eric S Fischer, Nathanael S Gray, Ralitsa R Madsen, Alex Toker
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Science signaling 17 (825) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Emily C Erickson, Inchul You, Grace E Perry, Aurélien J F Dugourd, Katherine Aleisha Donovan, Claire Crafter, Jeffrey W Johannes, Stuart Charles Williamson, Jennifer I Moss, Susana Ros, Robert E Ziegler, Simon T Barry, Eric S Fischer, Nathanael S Gray, Ralitsa R Madsen, Alex Toker
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Science signaling 17 (825) (2024)
Emily C Erickson, Inchul You, Grace E Perry, Aurélien J F Dugourd, Katherine Aleisha Donovan, Claire Crafter, Jeffrey W Johannes, Stuart Charles Williamson, Jennifer I Moss, Susana Ros, Robert E Ziegler, Simon T Barry, Eric S Fischer, Nathanael S Gray, Ralitsa R Madsen, Alex Toker
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Science signaling 17 (825) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer (2024)
Emily C Erickson, Inchul You, Grace E Perry, Aurélien J F Dugourd, Katherine Aleisha Donovan, Claire Crafter, Jeffrey W Johannes, Stuart Charles Williamson, Jennifer I Moss, Susana Ros, Robert E Ziegler, Simon T Barry, Eric S Fischer, Nathanael S Gray, Ralitsa R Madsen, Alex Toker
Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Science signaling 17 (825) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Cath Eberlein, Stuart Charles Williamson, Lorna Hopcroft, Susana Ros, Jennifer I Moss, James Kerr, Thomas A Kirkland, Elza C de Bruin, Shanade Dunn, Brandon Willis, Sarah J Ross, Claire Rooney, Simon T Barry
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. British journal of cancer 130 (8) (2024)
Lorna Hopcroft, Eleanor M Wigmore, Stuart Charles Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer 9 (1) (2023)
Lorna Hopcroft, Eleanor M Wigmore, Stuart Charles Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer 9 (1) (2023)
Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh C Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I Fisher, Eric T Gangl, Hilary J Lewis, Dawn Trueman, Neha Wali, Stuart Charles Williamson, Jennifer I Moss, Elodie Montaudon, Héloïse Derrien, Elisabetta Marangoni, Ricardo J Miragaia, Sladjana Gagrica, Pablo Morentin Gutierrez, Thomas Moss, Gareth A Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E Critchlow, James S Scott, Justin P O Lindemann, Simon T Barry, Teresa Klinowska, Christopher J Morrow, Larissa S Carnevalli
The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance. Cancer research (2023)
Lorna Hopcroft, Eleanor M Wigmore, Stuart Charles Williamson, Susana Ros, Cath Eberlein, Jennifer I Moss, Jelena Urosevic, Larissa S Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffman, Daniel Sutton, Stewart Jones, Richard J A Goodwin, Brandon S Willis, Claire Rooney, Elza C de Bruin, Simon T Barry
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ breast cancer 9 (1) (2023)
Sandra Cristea, Garry L Coles, Daniel Hornburg, Maya Gershkovitz, Julia Arand, Siqi Cao, Triparna Sen, Stuart Charles Williamson, Jun W Kim, Alexandros P Drainas, Andrew He, Laurent Le Cam, Lauren Averett Byers, Michael P Snyder, Kevin Contrepois, Julien Sage
The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer. Cancer research 80 (6) (2020)

Stuart Charles Williamson.css-eqlu8i{font-size:small;padding-left:4px;} (Stuart Williamson, Stuart C Williamson)

Publication Activity (10 Years)

Top Topics

Top Venues

Stuart Charles Williamson (Stuart Williamson, Stuart C Williamson)